LDHA and glioblastoma: The rationale of the drug composition in CUSP9 was to add drugs that both inhibit general growth factor-related signaling pathways (e.g., Akt, mTOR, and STAT), and specifically target the stem cell population in GBM (e.g., ALDH and hedgehog signaling) (Kast et al. 2013, 2014).